

Glioblastoma Awareness Day 2026

**CBTRUS**Central Brain Tumor Registry
of the United States

What is Glioblastoma?

Glioblastoma is the most commonly occurring malignant brain and other CNS tumor in the United States — making up 13.7% of all primary brain tumors and 52.2% of all malignant ones.

Survival

8 moAverage **survival time** after diagnosis**43%**chance of living **1 year** after diagnosis**7%**chance of living **5 years** after diagnosis**4.4%**chance of living **10 years** after diagnosis

Molecular Profile



Most glioblastomas share a common genetic pattern called "IDH-wildtype":

- 82.1% have the standard pattern (IDH-wildtype)
- 2.3% have an altered/mutated pattern (IDH-mutant)
- The remaining 13.2% are unknown.



Tumor Location

Frontal & Temporal Lobes Most Common
Malignant tumors overall cluster in the frontal (25.2%), temporal (17.8%), and parietal (10.5%) lobes. Glioblastoma follows a similar pattern: frontal 29.3%, temporal 25.0%, parietal 15.0%.

By the Numbers.

INCIDENCE RATE

3.28 per 100,000

About 3 in 100,000 people are diagnosed each year.

MEDIAN AGE

66 years

Median age at diagnosis. Risk climbs sharply after 40, peaking in the early 70s.

NEW CASES

13,930

Projected new U.S. diagnoses in 2025.

SEX DISTRIBUTION

**Male:** 4.07 per 100,000**Female:** 2.60 per 100,000

Race & Ethnicity



Rates per 100,000.

About This Data

REPORTING PERIOD **2018-2022**

CBTRUS is the leading source of population-based data on all primary brain and other central nervous system tumors in the United States. This fact sheet draws on the CBTRUS Statistical Report and the CBTRUS Glioblastoma Fact Sheet to help patients, families, and the public understand the disease behind Glioblastoma Awareness Day.

Data drawn from the CBTRUS Statistical Report: Primary Brain and Other CNS Tumors Diagnosed in the United States, published in Neuro-Oncology 27(S4).

Thank you Funders

Funding provided by the Centers for Disease Control and Prevention under Contract No. 75D30123P17556, the American Brain Tumor Association, the Musella Foundation for Brain Tumor Research & Information, Inc., the National Brain Tumor Society, the Pediatric Brain Tumor Foundation, Novocure, Jazz Pharmaceuticals, the Sontag Foundation, the Uncle Kory Foundation, the Don and Diane Kane Charitable Trust, the Josephine F. DeAngelis Memorial Fund, and the Zelda Dorin Tetenbaum Memorial Fund, as well as from private and in-kind donations.
*Contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC nor of the NCI.

